C 7617Alternative Names: c-7617
Latest Information Update: 03 Jul 2006
At a glance
- Originator Merck & Co
- Class Antidementias
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 03 Jul 2006 No development reported - Phase-I for Alzheimer's disease in USA (unspecified route)
- 17 Feb 2004 Phase-I clinical trials in Alzheimer's disease in USA (unspecified route)